WHO. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/. Accessed 4 Aug 2021.
Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19 - Preliminary report. N Engl J Med. 2020.
W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA; 2020.
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(7716):b2535.
Cogliati-Dezza F, Oliva A, Cancelli F, et al. Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Diagn Microbiol Infect Dis. 2021;100(2):115347.
Feng ZC, Li J, Yao SH, et al. Clinical factors associated with progression and prolonged viral shedding in COVID-19 patients: a multicenter study. Aging Dis. 2020;11(5):1069–81.
Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Resp J. 2020;56(1):2000799.
Yuan ML, Xu XX, Xia DP, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: a propensity score-based analysis. Shock. 2020;54(5):638–43.
Chen XD, Zhu BY, Hong WX, et al. Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19. Int J Infect Dis. 2020;98:252–60.
Hu ZG, Li SJ, Yang AL, et al. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19. Eur J Clin Microbiol Infect Dis. 2021;40(4):841–8.
Huang R, Zhu CW, Wang J, et al. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. Eur J Pharmacol. 2020;889:173556.
Li Q, Li WX, Jin YP, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study. Infect Dis Therapy. 2020;9:823.
Wells G, Shea B, O’Connell D, et al.. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed 3 April 2020.
IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open. 2016;6(7):e010247.
Spruance SL, Reid JE, Grace M, Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother. 2004;48(8):2787–92.
Zhang J, Yu KF. What’s the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690–1.
National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment (7th edition). http://kjfymeetingchina.org/msite/news/show/cn/3337.htm. Accessed 15 May 2020.
Peng FJ, Tu L, Yang YS, et al. Management and treatment of COVID-19: the Chinese experience. Can J Cardiol. 2020;36(6):915–30.
Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res Synth Meth. 2010;1(2):112–25.
Cao HR, Zhu XY, Zhou L, et al. Factors associated with delayed viral shedding in COVID-19 infected patients: a retrospective small-scale study. Resp Med. 2021;178:106328.
Chang D, Zhao P, Zhang DW, et al. Persistent viral presence determines the clinical course of the disease in COVID-19. J Allergy Clin Immunol Pract. 2020;8(8):2585.
Chen Q, Song Y, Wang L, et al. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study. Expert Rev Resp Med. 2020.
Chen YF, Li LJ. Influence of corticosteroid dose on viral shedding duration in patients with COVID-19. Clin Infect Dis. 2021;72(7):1298–1300.
Ding C, Feng XW, Chen YF, et al. Effect of corticosteroid therapy on the duration of SARS-CoV-2 clearance in patients with mild COVID-19: a retrospective cohort study. Infect Dis Therapy. 2020;9(4):943–52.
Fang XW, Mei Q, Yang TJ, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020;81(1):147–9.
Fu HY, Luo Y, Gao JP, et al. Effects of short-term low-dose glucocorticoids for patients with mild COVID-19. BioMed Res Int. 2020:2854186.
Gong Y, Guan L, Jin Z, Chen SX, Xiang GM, Gao BA. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old. J Med Virol. 2020;92(11):2551–5.
Hu FY, Yin G, Chen YP, et al. Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with coronavirus disease 2019. Clin Resp J. 2020;14(11):1067–75.
Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020;72(9):e373–81.
Ji JJ, Zhang JX, Shao ZY, Xie QF, Zhong L, Liu ZF. Glucocorticoid therapy does not delay viral clearance in COVID-19 patients. Crit Care. 2020;24(1):565.
Li TZ, Cao ZH, Chen Y, et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol. 2020;93:506.
Li YM, Meng QH, Rao X, et al. Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study. Crit Care. 2020;24(1):698–707.
Liang MY, Chen P, He M, et al. Corticosteroids treatment of patients with coronavirus disease 2019: a propensity score matching study. Curr Med Sci. 2021;41(1):24–30.
Liu J, Zhang S, Dong X, et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Investig. 2020;130(12):6417–28.
Liu ZB, Li X, Fan GH, et al. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect. 2020;27(1):112–7.
Lu YY, Liu F, Tong GL, et al. Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19. Signal Transduct Target Ther. 2021;6(1):107–17.
Ma Q, Qi D, Deng XY, et al. Corticosteroid therapy for patients with severe novel coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020;24(15):8194–201.
Ma YM, Zeng HH, Zhan ZJ, et al. Corticosteroid use in the treatment of COVID-19: a multicenter retrospective study in Hunan, China. Front Pharmacol. 2020;11:1198.
Masia M, Fernandez-Gonzalez M, Garcia JA, Padilla S, Gutierrez F. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. J Infect. 2020;82(3):414–51.
Ni Q, Ding C, Li YT, et al. Effect of low-to-moderate dose glucocorticoids on viral clearance in COVID-19: a retrospective study. Chin J Clin Infect Dis. 2020;13(1):21–4.
Qi L, Yang Y, Jiang DX, et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. Int J Infect Dis. 2020;96:531–7.
Shi D, Wu WR, Wang Q, et al. Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study. J Infect Dis. 2020;222(6):910–8.
Shu HM, He S, Sun Y, et al. Factors influencing viral clearance in mild COVID-19 and clinical characteristics of asymptomatic patients. Biomed Res Int. 2021;2021:5909612.
Spagnuolo V, Guffanti M, Galli L, et al. Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Sci Rep. 2020;10(1):21291.
Wu CM, Hou DN, Du CL, et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. Crit Care. 2020;24(1):643.
Xia Q, Xu KJ, Ni Q, et al. Clinical efficacy of methylprednisolone and the combined use of lopinavir/ritonavir with arbidol in treatment of coronavirus disease 2019. J Med Virol. 2021;93(7):4446–53.
Xu KJ, Chen YF, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis. 2020;71(15):799-806.
Zha L, Li SR, Pan LL, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–20.
Zuo Y, Liu YL, Zhong Q, Zhang K, Xu YH, Wang ZX. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: a retrospective study in two designated hospitals in Anhui, China. J Med Virol. 2020;92(11):2666–74.
Xiong LQ, Jin W, Hu XM, et al. Effect of glucocorticoid therapy on the prognosis of patients with severe and critical COVID-19: a single-center retrospective cohort study. Eur Rev Med Pharmacol Sci. 2021;25(2):1070–9.
Yousefifard M, Mohamed Ali K, Aghaei A, et al. Corticosteroids on the management of coronavirus disease 2019 (COVID-19): a systemic review and meta-Analysis. Iran J Public Health. 2020;49(8):1411–21.
Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–67.
Cao B, Gao H, Zhou B, et al. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med. 2016;44(6):e318–28.
Lee N, Chan K, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–9.
Ryoo SM, Kim WY, Sohn CH, et al. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. Influenza Other Respir Viruses. 2013;7(5):833–7.
Butler WT, Rossen RD. Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest. 1973;52(10):2629–40.
Van Mens SP, Meijvis SC, Grutters JC, Vlaminckx BJ, Bos WJ, Rijkers GT. Dexamethasone treatment has no effect on the formation of pneumococcal antibodies during community-acquired pneumonia. Clin Vaccine Immunol. 2012;19(5):811–3.
Di Castelnuovo A, Costanzo S, Antinori A, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter italian CORIST study. Thromb Haemost. 2021;121(8):1054–65.
Li J, Liao X, Zhou Y, et al. Comparison of associations between glucocorticoids treatment and mortality in COVID-19 patients and SARS patients: a systematic review and meta-analysis. Shock. 2021;56(2):215–28.
Mondi A, Lorenzini P, Castilletti C, et al. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021;105:532–9.